Immuron (Australia) Performance
| IMC Stock | 0.08 0 2.70% |
The company retains a Market Volatility (i.e., Beta) of 0.3, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Immuron's returns are expected to increase less than the market. However, during the bear market, the loss of holding Immuron is expected to be smaller as well. At this point, Immuron has a negative expected return of -0.33%. Please make sure to check out Immuron's maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to decide if Immuron performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Immuron has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:40 | Last Split Date 2014-11-17 |
1 | Immuron Full Year 2024 Earnings AU0.03 loss per share - Yahoo Finance | 10/03/2024 |
2 | Immuron Limited Showcases Promising Biopharmaceutical Innovations - TipRanks | 11/21/2024 |
| Begin Period Cash Flow | 17.2 M |
Immuron |
Immuron Relative Risk vs. Return Landscape
If you would invest 10.00 in Immuron on August 29, 2024 and sell it today you would lose (2.40) from holding Immuron or give up 24.0% of portfolio value over 90 days. Immuron is producing return of less than zero assuming 4.1606% volatility of returns over the 90 days investment horizon. Simply put, 37% of all stocks have less volatile historical return distribution than Immuron, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Immuron Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immuron's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immuron, and traders can use it to determine the average amount a Immuron's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0805
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMC |
Estimated Market Risk
| 4.16 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.33 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Immuron is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immuron by adding Immuron to a well-diversified portfolio.
Immuron Fundamentals Growth
Immuron Stock prices reflect investors' perceptions of the future prospects and financial health of Immuron, and Immuron fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immuron Stock performance.
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.41) % | ||||
| Operating Margin | (1.32) % | ||||
| Current Valuation | 5.84 M | ||||
| Shares Outstanding | 228 M | ||||
| Price To Book | 1.36 X | ||||
| Price To Sales | 3.58 X | ||||
| Revenue | 4.9 M | ||||
| Gross Profit | 1.74 M | ||||
| EBITDA | (6.19 M) | ||||
| Net Income | (6.94 M) | ||||
| Total Debt | 173.5 K | ||||
| Book Value Per Share | 0.06 X | ||||
| Cash Flow From Operations | (5.88 M) | ||||
| Earnings Per Share | (0.03) X | ||||
| Total Asset | 15.55 M | ||||
| Retained Earnings | (78.97 M) | ||||
About Immuron Performance
Assessing Immuron's fundamental ratios provides investors with valuable insights into Immuron's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Immuron is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Immuron is entity of Australia. It is traded as Stock on AU exchange.Things to note about Immuron performance evaluation
Checking the ongoing alerts about Immuron for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immuron help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immuron generated a negative expected return over the last 90 days | |
| Immuron has some characteristics of a very speculative penny stock | |
| Immuron has high historical volatility and very poor performance | |
| The company reported the revenue of 4.9 M. Net Loss for the year was (6.94 M) with profit before overhead, payroll, taxes, and interest of 1.74 M. | |
| Immuron generates negative cash flow from operations | |
| About 18.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Immuron Limited Showcases Promising Biopharmaceutical Innovations - TipRanks |
- Analyzing Immuron's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immuron's stock is overvalued or undervalued compared to its peers.
- Examining Immuron's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immuron's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immuron's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immuron's stock. These opinions can provide insight into Immuron's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immuron Stock Analysis
When running Immuron's price analysis, check to measure Immuron's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuron is operating at the current time. Most of Immuron's value examination focuses on studying past and present price action to predict the probability of Immuron's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuron's price. Additionally, you may evaluate how the addition of Immuron to your portfolios can decrease your overall portfolio volatility.